The economic consequences of US FDA new drug approvals: evidence from Taiwan pharmaceutical and biotech companies
- 3 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Innovation
- Vol. 23 (3), 354-374
- https://doi.org/10.1080/14479338.2020.1786389
Abstract
This study examines the association between the new drug approvals released by the US Food and Drug Administration (FDA) and subsequent market stock price reactions for listed pharmaceutical and biotech companies in Taiwan. We find that new drug approvals released by the US FDA lead to significantly positive stock price cumulative abnormal returns (CARs) in most stages of the new drug approval process, in particular, for the phase 3 stage. This implies that public investors are more willing to invest in the later stages of the US FDA approval process due to the high failure rate of drug verification. We also find that research and development (R&D) investment has significantly positive impacts on CARs. Since R&D investments may substantially reduce the taxes and operating costs of pharmaceutical and biotech companies, they are positively related to stock price returns and serve as an important indicator for market investors. Finally, we find that the effect of R&D investment on CARs associated with FDA approvals is more prominent in the period after the passage of the ‘Taiwanese Biotech and New Pharmaceutical Development Act’, indicating that tax incentives or policy effects indeed influence market responses.Keywords
Funding Information
- National Science Council, Taiwan, ROC (103-2410-H-006 −026 -MY2)
This publication has 32 references indexed in Scilit:
- Stock Market Returns and Clinical Trial Results of Investigational Compounds: An Event Study Analysis of Large Biopharmaceutical CompaniesPLOS ONE, 2013
- A research note on market creation in the pharmaceutical industryJournal of Business Research, 2011
- Is the Risk of Bankruptcy a Systematic Risk?The Journal of Finance, 1998
- Success rates for new drugs entering clinical testing in the United StatesClinical Pharmacology & Therapeutics, 1995
- Wealth effects of food and drug administration (FDA) decisionsManagerial and Decision Economics, 1994
- A test of the free cash flow hypothesis: The case of bidder returnsJournal of Financial Economics, 1991
- The Impact of New Product Introductions on the Market Value of FirmsThe Journal of Business, 1991
- Corporate research and development expenditures and share valueJournal of Financial Economics, 1990
- Organizational forms and investment decisionsJournal of Financial Economics, 1985
- Methodological Issues Related to the Estimation of Financial Distress Prediction ModelsJournal of Accounting Research, 1984